To read the full story, subscribe or sign in.

Fosun Pharma to buy out Henlius in $691.7M merger deal

June 25, 2024

Shanghai Fosun Pharmaceutical Co. Ltd announced it will buy out partner Shanghai Henlius Biotech Inc. for up to HKD$5.4 billion (US$691.7 million), according to a joint announcement on the Hong Kong Stock Exchange.

BioWorld BioWorld Asia Deals and M&A Cancer Biosimilar Asia-Pacific China NMPA

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 17, 2025.

Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM

BioWorld

The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

BioWorld Science

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...

PHD inhibitors reported in Akebia Therapeutics patent

BioWorld Science

Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.